Full-Time

Chromatography Principal Scientist

Posted on 5/20/2025

Deadline 8/4/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$122.3k - $176.6k/yr

Senior

Cambridge, MA, USA

US and Puerto Rico Residents Only

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • A Masters degree or equivalent in Analytical Chemistry or related field with a minimum of 4 years of experience in the pharmaceutical/biotech industry.
  • Expertise in the operation of LC and GC.
  • Familiarity with the operation of potentiometry titrator, and TLC from multiple manufacturers.
  • Extensive experiences in method development using HPLC/UPLC and GC.
  • Experiences in analytical method validation.
  • Record of adhering to and promoting lab safety practices.
  • Good communications skills.
Responsibilities
  • Develop specific and robust analytical methods using equipment including HPLC, UHPLC, GC, TLC, and potentiometry and be responsible for validating the methods when necessary.
  • Analyze synthetic molecules mainly by HPLC/UHPLC, GC, potentiometry, and TLC.
  • Perform quantification of impurities.
  • Perform mass balance studies.
  • Design and implement analytical strategies for synthesis intermediates and raw materials.
  • Develop effective collaborations with others within project teams and between analytical groups.
  • Generate technical reports independently.
  • Share knowledge and experience of analytical method development for synthetic molecules.
  • Introduce innovative analytical approaches to facilitate optimal decision-making.
  • May serve as a project lead.
Desired Qualifications
  • In-depth understanding of the separation principles of LC and GC.
  • Deep expertise in chromatography method development and trouble shoots.
  • Knowledge of QbD concepts, specification setting, and cGMP, with experience in contributing to regulatory submission.
  • Communicates effectively in individual and group settings and collaborate effectively in a multi-disciplinary team setting.
  • Demonstrated project management skills.
  • Consistent record of collaboration with scientists and other stakeholders at external enterprises.
  • Advanced scientific network in the industry and academia.
  • Record of patents and publications.

Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new medicines and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medications, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, which help to maintain a steady pipeline of new products. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's Q1 2025 profit grew by 20%, indicating strong financial performance.
  • The integration of AI in R&D accelerates drug discovery and reduces costs.
  • mRNA technology expansion offers new drug development opportunities for Sanofi.

What critics are saying

  • Increased competition in immunology may impact Sanofi's market share.
  • Potential regulatory delays could affect the launch of new drugs like tolebrutinib.
  • Acquisitions may lead to integration challenges and operational disruptions.

What makes Sanofi unique

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The on-body injector for Sarclisa offers a novel delivery method for multiple myeloma.
  • Dupixent's approval for chronic spontaneous urticaria marks a significant therapeutic advancement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.

INACTIVE